甲基(3S)-1-[(2S)-3-(4-溴-1,3-噻唑-2-基)-2-[(叔丁氧羰基)氨基]丙酰基]二嗪烷-3-甲酸酯

KRAS G12D inhibitor Daraxonrasib key intermediate (CAS No. 2641451-75-2) is a key pharmaceutical intermediate for the synthesis of KRAS-targeted anticancer drugs, with molecular formula C17H25BrN4O5S and molecular weight about 477.4. This compound is an advanced pharmaceutical intermediate used in the synthesis of kras-targeted anticancer drugs, including covalent inhibitors developed for the treatment of solid tumors such as non-small cell lung cancer and colorectal cancer.. This product is suitable for laboratory research, analytical method development, and quality control applications. Our company, located in Hangzhou and Hubei, China, supplies this compound with guaranteed purity of 98% and offers standard packaging of 1 g, 5 g and 10 g to meet different customer requirements. The minimum order quantity is 100 mg. We are committed to providing high-quality products, competitive pricing, timely delivery and professional technical support. For detailed specifications, certificates of analysis and bulk quotations, please feel free to contact us.